Stock Scorecard



Stock Summary for Sage Therapeutics Inc (SAGE) - $6.53 as of 5/27/2025 2:22:41 PM EST

Total Score

13 out of 30

Safety Score

29 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for SAGE

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for SAGE

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for SAGE

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for SAGE

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for SAGE (29 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for SAGE

BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut 5/1/2025 4:44:00 PM
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y 4/30/2025 4:17:00 PM
Sage Therapeutics, Inc. ( SAGE ) Reports Q1 Loss, Misses Revenue Estimates 4/29/2025 9:15:00 PM
Analysts Estimate Agios Pharmaceuticals ( AGIO ) to Report a Decline in Earnings: What to Look Out for 4/24/2025 2:02:00 PM
Can Biogen Keep the Beat Streak Alive This Earnings Season? 4/24/2025 10:53:00 AM
Sage Therapeutics, Inc. ( SAGE ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release 4/22/2025 2:01:00 PM
Clearside Biomedical, Inc. ( CLSD ) Reports Q4 Loss, Tops Revenue Estimates 3/27/2025 9:20:00 PM
US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert 3/27/2025 9:56:00 AM
KB Home Posts Downbeat Results, Joins UniFirst, Oklo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - KB Home ( NYSE:KBH ) , China Yuchai Intl ( NYSE:CYD ) 3/25/2025 12:38:00 PM
Notice to Long-Term Shareholders of Fluence Energy, Inc. ( NASDAQ: FLNC ) ; Kyverna Therapuetics, Inc. ( NASDAQ: KYTX ) ; Mercury Systems, Inc. ( NASDAQ: MRCY ) ; and Sage Therapeutics, Inc. ( NASDAQ: SAGE ) : Grabar Law Office Is Investigating Claims on Your Behalf - Kyverna Therapeutics ( NASDAQ:KYTX ) , Fluence Energy ( NASDAQ:FLNC ) 3/17/2025 7:01:00 PM

Financial Details for SAGE

Company Overview

Ticker SAGE
Company Name Sage Therapeutics Inc
Country USA
Description Sage Therapeutics, Inc., a biopharmaceutical company, develops and markets drugs to treat disorders of the central nervous system. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date 7/29/2025

Stock Price History

Last Day Price 6.53
Price 4 Years Ago 42.54
Last Day Price Updated 5/27/2025 2:22:41 PM EST
Last Day Volume 770,577
Average Daily Volume 877,480
52-Week High 13.47
52-Week Low 4.62
Last Price to 52 Week Low 41.34%

Valuation Measures

Trailing PE N/A
Industry PE 21.34
Sector PE 39.72
5-Year Average PE -4.13
Free Cash Flow Ratio 9.07
Industry Free Cash Flow Ratio 16.88
Sector Free Cash Flow Ratio 31.24
Current Ratio Most Recent Quarter 9.13
Total Cash Per Share 0.72
Book Value Per Share Most Recent Quarter 6.55
Price to Book Ratio 1.00
Industry Price to Book Ratio 34.13
Sector Price to Book Ratio 29.89
Price to Sales Ratio Twelve Trailing Months 8.63
Industry Price to Sales Ratio Twelve Trailing Months 146.12
Sector Price to Sales Ratio Twelve Trailing Months 39.44
Analyst Buy Ratings 0
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 62,621,000
Market Capitalization 408,915,130
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 26.01%
Reported EPS 12 Trailing Months -5.80
Reported EPS Past Year -1.00
Reported EPS Prior Year -6.23
Net Income Twelve Trailing Months -354,397,000
Net Income Past Year -400,666,000
Net Income Prior Year -541,489,000
Quarterly Revenue Growth YOY 78.00%
5-Year Revenue Growth 43.12%
Operating Margin Twelve Trailing Months -476.00%

Balance Sheet

Total Cash Most Recent Quarter 45,224,000
Total Cash Past Year 81,021,000
Total Cash Prior Year 70,992,000
Net Cash Position Most Recent Quarter 45,224,000
Net Cash Position Past Year 81,021,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 465,089,000
Total Stockholder Equity Prior Year 799,530,000
Total Stockholder Equity Most Recent Quarter 409,848,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -311,090,000
Free Cash Flow Per Share Twelve Trailing Months -4.97
Free Cash Flow Past Year -267,194,000
Free Cash Flow Prior Year -541,138,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.16
MACD Signal -0.17
20-Day Bollinger Lower Band 6.07
20-Day Bollinger Middle Band 7.21
20-Day Bollinger Upper Band 8.35
Beta 0.20
RSI 43.33
50-Day SMA 7.74
150-Day SMA 24.13
200-Day SMA 27.83

System

Modified 5/27/2025 9:43:14 AM EST